SCHEMBL3595736

SCHEMBL3595736

CC(C)(C)OC(=O)C1CNCC2C(=O)N(c3cccc(Oc4ccccc4)c3)CN12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FKBP1A P62942 1/20 0.36
THRB P10828 1/20 0.36
CHRNB2 P17787 1/20 0.34
CHRNB4 P30926 1/20 0.34
CHRNA3 P32297 1/20 0.34
CHRNA7 P36544 1/20 0.34
CHRNA4 P43681 1/20 0.34
USP30 Q70CQ3 1/20 0.34
MGLL Q99685 1/20 0.34
GHSR Q92847 1/20 0.34
MAPT P10636 3/20 0.33
TP53 P04637 1/20 0.33
NR1H2 P55055 2/20 0.33
NR1H3 Q13133 2/20 0.33
HIF1A Q16665 1/20 0.33
KYAT1 Q16773 1/20 0.33
KYAT3 Q6YP21 1/20 0.33
AADAT Q8N5Z0 1/20 0.33
CYP2C9 P11712 2/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3601852 0.90 MAPT (0.40) MAPTTP53ALDH1A1
SCHEMBL3604816 0.90 GPR119 (0.36) USP30NR1H2NR1H3
SCHEMBL3607457 0.89 USP30 (0.44) USP30NR1H2NR1H3SLC5A1DDB1
SCHEMBL3605596 0.88 ALDH1A1 (0.37) ALDH1A1DDB1CRBN
SCHEMBL3597127 0.87 DDB1 (0.34) USP30NR1H2NR1H3DDB1CRBN
SCHEMBL3606120 0.87 POLB (0.37) TP53ALDH1A1DDB1CRBN
SCHEMBL3601055 0.87 GPR119 (0.41) MAPTNR1H2NR1H3ALDH1A1
SCHEMBL3606731 0.87 OPRM1 (0.38) USP30NR1H2NR1H3ALDH1A1DDB1
SCHEMBL3603893 0.87 USP30 (0.35) USP30NR1H2NR1H3SLC5A1DDB1
SCHEMBL3609983 0.86 ALDH1A1 (0.36) USP30NR1H2NR1H3ALDH1A1DDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004249-A1 Bicyclic heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-07 US disclosed
EP-2039695-A1 BICYCLIC HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2009-03-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004249-A1 Bicyclic heterocyclic compound and use thereof HTR2C, HTR5A, HTR2A FKBP1A 2215/4885THRB 596/4885CHRNB2 284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.